Biodesix posts higher than expected earnings, deeper losses
BOULDER — Biodesix Inc. (Nasdaq: BDSX) had a mixed period in the first quarter of 2021, beating analyst estimates on its earnings but posting a deeper loss than expected.
The Boulder developer of lung cancer tests reported revenues of $28.9 million and a loss of 26 cents per share, beating consensus estimates by $2.67 million and missing by 9 cents, respectively, according to data from finance site Seeking Alpha.
Approximately $23.2 million of that revenue came from the company’s COVID-19 testing and processing offerings, amounting to an 8% increase in that segment from the final quarter of 2020.
The company also said its…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
BOULDER — Even with the COVID-10 pandemic several years in the rearview mirror, it remains…
-
Boulder Community Health this month became the first facility in Colorado to offer patients a…
-
LOVELAND — The Stinging Nettle has taken up residence in downtown, filling a hole recently…
-
Nextera Healthcare LLC and ImagineMD have combined to form a single direct-primary-care organization for employer…
